Abstract Search

ea0089c7 | Clinical – Chemo/SSA/Biologics | NANETS2022

Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate

MPH Taymeyah Al-Toubah , MD Eleonora Pelle , MD Jonathan Strosberg

Background: The treatment landscape for neuroendocrine tumors includes alkylating-agent chemotherapy and peptide receptor radiotherapy (PRRT) with 177Lu-Dotatate. The risk of MDS/AML associated with 177Lu-Dotatate is approximately 2-3%. Several small prior studies have suggested substantially higher rates of MDS/AML (approximately 10%) in patients who have also received alkylating agent chemotherapy with streptozocin or temozolomide, either combined with PRRT or sequentially. ...

2 shares

ea0089b3 | Basic Science | NANETS2022

Development of a Novel Anti-SSTR Bispecific T-Cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors

Pelle Eleonora , Cives Mauro , Medina Elliot , Mason Charlotte C. , Snedal Sebastian A. , Bustos-Perez Xiomar E. , Tordesillas Leticia , Gomez Fontela Miguel , Marques Rossetti Renata A. , Maiorano Gabriele , Luca Vince , Hwu Patrick , Abate-Daga Daniel , Strosberg Jonathan

Background: Well-differentiated neuroendocrine tumors (NETs) are characterized by the overexpression of somatostatin receptors (SSTRs). To efficiently engage and activate tumor infiltrating lymphocytes against NET cells, we designed a novel bispecific T-cells engager (BiTE) composed of 2 molecules of somatostatin-14 (SST14), the hormone that physiologically binds SSTRs, linked with a single chain variable fragment (scFV)-based anti-CD3.Methods: The optim...

0 shares

Endocrine Abstracts

Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate

Development of a Novel Anti-SSTR Bispecific T-Cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors

BiosciAbstracts